Paris, May 25, 2026, 15:02 CEST
- Sanofi shares added 0.47% to 77.24 euros on the Paris market. The CAC 40 climbed 1.76%.
- The move happened during a regular Euronext Paris session, even with Whit Monday.
- European risk appetite picked up as hopes grow for U.S.-Iran peace, but Sanofi’s pipeline is still the main story for the stock.
Sanofi shares gained Monday. The French drugmaker missed much of Paris’s rally as traders went for cyclicals and showed caution on pipeline risk in large pharma.
Shares traded 0.47% higher at 77.24 euros at 15:02 local, with volume under 400,000 shares. The CAC 40 was up 1.76% at 8,258.84, according to Boursorama data. Brent crude dropped over 6%.
Sanofi is in focus as investors weigh it against a rising European stock market on Monday and the company’s slower path of drug launches, research, and the outlook for Dupixent, its top growth driver.
Paris traded as usual on May 25, Whit Monday. The Euronext 2026 calendar showed May 25 as a full session in Paris, with Euronext Paris running from 9:00 a.m. to 5:30 p.m. CEST.
European shares climbed to their highest in over two months, lifted by hope from the U.S.-Iran talks and relief on the energy price front. Banks and airlines outperformed. Trading stayed thin as both the U.S. and UK had market holidays.
Sanofi had no new release out over the weekend. The company’s media page last showed a press release dated May 18, detailing phase 2 data for efdoralprin alfa in alpha-1 antitrypsin deficiency, a genetic disease affecting lungs and liver.
Sanofi’s efdoralprin alfa, picked up in the $2.2 billion buyout of Inhibrx, delivered higher AAT protein levels than the current weekly standard in a 97-patient study, Reuters said. Sanofi rare disease medical chief Alaa Hamed said switching to less frequent shots could win over patients who have to get weekly doses.
Sanofi put up higher numbers in the first quarter. In April, the drugmaker reported sales up 13.6% at constant exchange rates, so without currency effects. Business EPS climbed 14.0% on the same measure. Interim CEO Olivier Charmeil said it was a “strong start to 2026.” Guidance for high single-digit sales growth this year was unchanged. Sanofi
Sanofi is in the middle of a management shakeup. Shareholders have backed Belén Garijo as director and CEO starting May 1. Chairman Frédéric Oudéa said the board is focusing on “strengthen[ing] execution discipline” and driving science to long-term results. Sanofi
Competitive risks are on the table. China’s commerce ministry brought in Sanofi, Novartis, Merck and Eli Lilly for a roundtable on Friday, the ministry said, as reported by Reuters. Market access and policy risk are concerns for big drugmakers across the board, not just Sanofi.
Monday’s market tone may be fragile. Kyle Rodda, senior financial market analyst at Capital.com, told Reuters the Iran-U.S. “deal” might amount to “little more than an extended ceasefire,” as questions on nuclear and Strait of Hormuz issues are still open. If oil prices recover or investors go back to risk-off, the lift for Sanofi could disappear, forcing the focus back to whether new products can balance future risks for Dupixent.
